Cencora agreed to distribute Kite’s FDA-approved CAR T-cell therapies Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) across the U.S., aligning distribution with Kite’s expanding network of authorized treatment centers. The arrangement is designed to reduce administrative burden for providers by leveraging Cencora’s specialty distribution infrastructure. The contract targets operational friction points rather than new clinical evidence, but it can materially affect real-world access and treatment site throughput for cell therapies. For hospitals and community oncology practices, distribution partners can influence logistics, order management, and time-to-treatment coordination. The announcement also underscores how payers and providers are increasingly depending on distribution models to scale complex therapies without increasing procedural burden.